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KEY LEARNINGS/OUTCOMES 11 
After reading this article, you should: 12 
• Understand the relationship between feline coronavirus and feline infectious 13 
peritonitis (FIP), and how this impacts transmission and diagnosis 14 
• Be able to list commonly identified findings on history, physical examination and 15 
routine clinicopathological tests that raise concern for FIP in a sick cat 16 
• Know how to diagnose probable FIP in a suspected case, and how to definitively 17 
diagnose FIP when this is necessary 18 
• Be aware of the current treatment options for a cat diagnosed with FIP, including 19 
recent advancements in this field 20 
• Be able to discuss possible methods to reduce risk of FIP within an multicat 21 
household 22 





Feline coronavirus (FCoV) infection in cats is common, usually only causing mild intestinal 26 
signs such as diarrhoea. It is highly infectious and found worldwide. A sequela of FCoV 27 
infection, feline infectious peritonitis (FIP) is a common cause of death in young cats, 28 
occurring in up to 10% of cats infected with FCoV. Although suspicion of FIP is frequent in 29 
sick, particularly young, cats, obtaining a definitive diagnosis using non- or minimally-30 
invasive approaches is difficult.  31 
 32 
Epidemiology 33 
Coronaviruses are relatively large, enveloped, positive-sense, single-stranded RNA viruses 34 
(see Figure 1 and Figure 2). They exhibit a high rate of mutation during replication and 35 
therefore exist as clusters of genetically diverse populations. Cats worldwide have been 36 
found to be infected with FCoV, with the exception of cats on a small number of isolated 37 
islands. 38 
 39 
Two serotypes of FCoV are recognised: Type 1, which represents the vast majority of field 40 
strains, and Type 2. The latter arises following recombination events between Type 1 FCoV 41 
and canine coronavirus. The two serotypes are distinguished primarily by differences in 42 
their transmembrane spike (S) glycoprotein. The S glycoprotein (see Figure 2) mediates 43 
binding to and entry of host cells.  44 
 45 
Infection with FCoV is very common, with 35% of the owned domestic cat population having 46 
detectable antibodies to FCoV indicating exposure (combined data from the eight 47 
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serological studies listed in (Drechsler et al., 2011)). In single cat households (combined 48 
data), seroprevalence reduces to 21%, but correspondingly in multi-cat households it can be 49 
over 90% (Addie et al., 2000). Most infections are transient (although reinfection is 50 
common) with only a small percentage becoming persistent ‘carriers’ or ‘chronically 51 
shedding’ cats (Kipar and Meli, 2014). 52 
 53 
Transmission and Pathogenesis  54 
Transmission is primarily faeco-oral, with litter boxes representing the principal source of 55 
infection amongst cats within a household. In breeding catteries, kittens commonly become 56 
infected at a young age, mostly at 5-6 weeks (Addie and Jarrett, 1992), as maternally 57 
derived antibodies have started to wane. Nose to nose contact is considered an uncommon 58 
route, and transplacental is considered rare. Experimentally, infection has been transmitted 59 
by parenteral injection of virus derived from cats with FIP. 60 
 61 
Small intestinal villi enterocytes are the primary point of host cell entry and replication. In 62 
most cases, FCoV infection is subclinical or results in only mild gastrointestinal signs (e.g. 63 
diarrhoea, vomiting). However, occasionally more severe gastrointestinal disease is seen. 64 
Subclinical FCoV infection was previously believed to be confined to the intestinal tract, but 65 
we now know that healthy FCoV-infected cats develop a detectable low-level viraemia 66 
during acute infection (Kipar et al., 2010). In a small percentage of cases FCoV infection 67 
results in feline infectious peritonitis (FIP), which typically occurs sporadically. Occasional 68 
outbreaks of FIP in multi-cat households or shelters affect a larger percentage of cats 69 




In FIP, virus-laden monocytes attach to the walls of small veins and release inflammatory 72 
cytokines that damage the endothelial basal lamina (Kipar and Meli, 2014). This results in 73 
extravasation of monocytes (which mature into tissue macrophages) and proteinaceous 74 
fluid. In effusive (a.k.a. ‘wet’) FIP, this extravasation of proteinaceous fluid is evident as fluid 75 
accumulations within body cavities. In non-effusive (a.k.a. ’dry’) FIP, the extravasated 76 
macrophages recruit other inflammatory cells and result in perivascular granulomata, which 77 
may appear grossly as a mass lesion (Figure 3 and Figure 4 A). The role of other cytokines, 78 
including interferon gamma and tumour necrosis factor-alpha (TNF-), in the pathogenesis 79 
of FIP is incompletely understood, but is thought to be significant (Kipar and Meli, 2014). 80 
The mesenteric lymph nodes (MLNs) may represent an important site in which the host 81 
immune response to FCoV plays a role in the outcome of infection, as MLNs are presumed 82 
to be the first site of FCoV replication outside the intestinal tract and before 83 
monocyte/macrophage infection occurs (Malbon et al., 2019). 84 
 85 
Viral factors are important in the pathogenesis of FIP. As mentioned earlier, the S 86 
glycoprotein of FCoV mediates host cell entry, with mutations in the S gene influencing cell 87 
tropism (Kipar and Meli, 2014). Mutations at different sites within the S gene have been 88 
detected with increased frequency in FIP tissue-derived FCoVs, as compared to faecally-89 
shed FCoV from clinically ‘healthy’ cats (Chang et al., 2012, Licitra et al., 2013). This has led 90 
to suggestions that some of these mutations could be a useful target in differentiating cats 91 
with FIP from cats without. Unfortunately, a recent large-scale study suggested that one of 92 
these sets of mutations, involving the fusion peptide, was more indicative of systemic FCoV 93 
infection, occurring in FCoV viraemic cats with and without FIP with equal frequency, rather 94 
than FIP per se (Barker et al., 2017). Other viral factors mediating effective and sustained 95 
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replication in monocytes, and activation of infected monocytes, are also likely to be 96 
important for the development of FIP following systemic FCoV infection. Very recently there 97 
has also been suggestion that specific viral mutations could be associated with tissue 98 
tropism (Andre et al., 2019). 99 
 100 
Host factors contributing to the immune response such as genetic background (e.g. breed-, 101 
line- or individual-specific) and maturity (e.g. age; history of prior exposure to infectious 102 
agents) likely play an important role in FIP development. Host factors are inextricably linked 103 
with environmental factors such as stress (e.g. cat-cat interactions; novel experiences such 104 
as rehoming, vaccination, surgery; resource accessibility) and overcrowding, which 105 
themselves may lead to increased environmental viral burden, increased viral replication 106 
within cats and support FIP development.  107 
 108 
Clinical signs associated with FIP 109 
The variability in the extent and distribution of both vasculitis and perivascular granulomata 110 
underlies one of the difficulties in diagnosing FIP. Clinical signs of FIP can change over time, 111 
necessitating repeated clinical examinations to detect newly apparent pathology. Non-112 
specific, often waxing and waning, clinical signs (see Table 1) attributable to the systemic 113 
inflammatory response frequently occur in cats both with and without detectable effusions, 114 
with FIP a significant differential for pyrexia of unknown origin (Spencer et al., 2017). 115 
Although, it should be noted that the absence of these signs does not rule out FIP. 116 
  117 
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Table 1 Commonly encountered features of signalment, history, and physical examination 118 
seen in cats with feline infectious peritonitis.  119 
Signalment Young (often <2 years); male; breed* 
History Background: Recent stress (vaccination; rehoming; new cat; 
surgery); multicat household (current / historical) 
Health: weight loss / failure to thrive; inappetence / 
anorexia; lethargy; pyrexia of unknown origin (non-
responsive to antibiotics; +/- fluctuating); behavioural 
change, ataxia, seizures 
Physical examination Abdominal distention / fluid thrill [ascites]; palpable mass; 
uveitis; jaundice; pyrexia; restrictive dyspnoea with dull lung 
sounds [pleural effusion]; neurological deficits; 
lymphadenopathy 
* Non-pedigree cats make up the majority of cats presenting with FIP (80% in a recent study 120 
(Richards, 1995)). However, various prevalence studies have identified increased incidence 121 
in certain pedigree breeds. The breeds identified of having increased risk vary from country 122 
to country, suggestive of either country-specific blood lines being more of a factor or 123 
reporting bias within the local pedigree cat communities. 124 
 125 
Although effusive FIP is regarded as being 3-4 times more common than non-effusive FIP 126 
(Kipar and Meli, 2014, Riemer et al., 2016), and the distinction between the two forms is 127 
important for diagnostic purposes, there is considerable overlap between them. Cases with 128 
effusive FIP often have pyogranulomatous lesions visible at post-mortem examination, 129 
whilst many cats with non-effusive FIP go on to develop effusions. Effusive FIP is often acute 130 
in nature, progressing within a few days or weeks; whereas non-effusive FIP tends to be 131 
more chronic, progressing over a few weeks to months. In effusive FIP, effusions may form 132 
in one or more body cavity, with abdominal effusion leading to a clinical presentation of 133 
ascites and abdominal distension being the most common manifestation. Cats with pleural 134 
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effusion often develop dyspnoea, whereas cats with pericardial effusion rarely show signs of 135 
cardiac tamponade. Occurring only rarely, scrotal effusion leads to scrotal enlargement in 136 
entire males. Non-effusive FIP is often more difficult to diagnose, particularly in the earlier 137 
stages of disease, as vague non-specific signs may be all that can be seen. More specific 138 
signs depend on the organs affected by the granulomatous lesions, often the central 139 
nervous system (CNS), eyes, or abdominal organs (e.g. liver, MLNs, kidney, gastrointestinal 140 
tract); however, any tissue can be affected and primary involvement of the lungs or skin 141 
have been described. 142 
 143 
In sick cats, careful neurological and ocular examination may reveal changes that support a 144 
diagnosis of FIP, as well as indicating a potential source of samples for testing. Neurological 145 
signs associated with focal, multifocal or diffuse changes in the CNS may be seen in up to 146 
30% of cats with FIP, and for some these are the only signs noted (Figure 5); this makes FIP a 147 
common differential for neurological disease, particularly in the young cat. Commonly 148 
reported signs in FIP with neurological involvement include ataxia (with varying degrees of 149 
tetra- or paraparesis), hyperaesthesia, head tilt, nystagmus, seizures, behavioural change, 150 
mental state change, cranial nerve deficits and postural reaction deficits; however, 151 
differentiating subtle neurological signs from those exhibited by systemically unwell cats 152 
may not be possible. Similarly, FIP is a major differential for uveitis (Figure 6) with anterior 153 
and posterior uveitis commonly identified in cats with both effusive and non-effusive FIP, 154 
particularly when examined by an experienced clinician.  155 
 156 
Where FIP manifests in the intestinal tract and/or regional lymph nodes (sometimes called 157 
“focal FIP”, although the disease is still systemic) it can present as a palpable abdominal 158 
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mass (see Figure 4) that must be differentiated from neoplasia, toxoplasmosis or other 159 
granulomatous disease (e.g. mycobacterial infection) (Kipar et al., 1999, Pedersen, 2009). 160 
Where the lesion involves the intestinal wall clinical signs may include vomiting, diarrhoea 161 
or constipation, or signs referable to an obstructive or protein-losing enteropathy may be 162 
seen. 163 
 164 
Diagnosis (see Figure 7) 165 
A high index of suspicion can be obtained from a combination of signalment, history, and 166 
physical examination (Table 1). However, none are pathognomonic for FIP and other 167 
common differential diagnoses (Table 2) should be considered when performing further 168 
investigation. 169 
 170 
Routine clinicopathological tests (Table 3) may indicate the presence of a chronic systemic 171 
inflammatory response, further supporting a clinical suspicion of FIP; however, no 172 
clinicopathological changes are diagnostic for FIP and, in some cats, routine blood analysis 173 
can be unremarkable. This is compounded by both vets (and owners) suspecting FIP earlier 174 
in the course of the disease process, so reducing the negative predictive power of some 175 
findings (e.g. absence of hyperglobulinaemia) (Stranieri et al., 2017).  176 
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Jaundice Effusion Ocular CNS Mass 
lesion 
Notes 
Toxoplasmosis ✓ ✓ ✓ ✓ ✓ ✓ History – Fed raw diet or hunter (also vertical transmission in 
kittens) 
Differences – Hyperglobulinaemia uncommon 
Diagnosis – Cytological identification of organisms on aspirates; PCR 
of aspirates or CSF; paired Toxoplasma serology (IgM & IgG) 
Lymphocytic 
cholangitis 
✓ ✓ ✓ 
(ascites) 
   History – Persians may be over-represented 
Differences – Usually (not always) associated with increased hepatic 
enzyme activities (primarily cholestatic). Cats often relatively well 
and normothermic 




✓ ✓ ✓ ✓ ✓ ✓ Can affect cats of any age, particularly lymphoma. Jaundice may be 
present particularly with hepatic involvement 
Diagnosis – Cytology of fluid or aspirates; biopsy 
Mycobacterial 
disease 
✓  ✓  ✓ ✓ ✓ 
(often 
LNs) 
History –Hunter or outdoor access (geographical variation), fed raw 
diet 
Differences – Usually minimal to no effusions. Usually (not always) 
relatively well and normothermic. Pulmonary signs (tachypnoea; 
cough) not uncommon 
Diagnosis – Ziehl-Neelsen stain of aspirates or biopsy; interferon- 
release assay; mycobacterial PCR or culture of aspirate or biopsy 
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Pancreatitis ✓ ✓ ✓ 
(ascites) 
  ✓ 
(pancreas) 
Differences – Usually (not always) normothermic. Ascites, where 
present, usually small volume with high cellularity (non-degenerate 
neutrophils) 




virus (FIV) / feline 
leukaemia virus 
(FeLV) 
✓   ✓ ✓ ✓ 
(LNs) 
History – Outdoor or ‘stray’; entire adult with unknown mating 
activity (especially FIV) 
Differences – Common differential for lymphadenopathy and/or 
uveitis. FeLV may be associated with neoplasia (especially 
lymphoma) 
Diagnosis – FIV antibody / FeLV antigen serology (positive results 
should be confirmed) 
Sepsis ✓ ✓ Infection can involve different organ 
systems (e.g. kidney; liver; uterus; 
heart) or body cavities (e.g. pyothorax; 
septic peritonitis) 
Cats are often very sick, e.g. pyrexia may have progressed to 
hypothermia with onset of shock 
Diagnosis – haematology suggestive (leukocytosis or neutropenia; 
left shift and toxic change); hypoglycaemia may be present; imaging; 
cytology (degenerate neutrophils; intracellular bacteria) and culture 
of fluid or aspirates* 
Septic peritonitis ✓  ✓ 
(ascites) 
   Pyrexia common. Most frequently associated with gastrointestinal 
or urinary tract perforation 
Differences – Ascites with high cellularity (degenerate neutrophils; 
intracellular bacteria) 
Diagnosis – cytology and culture of fluid or aspirates* 
Pyothorax ✓ ✓ ✓ 
(pleural) 
   Usually pyrexic 
Differences – Pleural effusion with high cellularity (degenerate 
neutrophils; intracellular bacteria) 
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Diagnosis – cytology and culture of fluid or aspirates* 
Congestive heart 
failure (CHF) 




   History – Some breeds are predisposed to cardiomyopathy (e.g. 
Ragdoll; Maine Coon) with increased risk of CHF at a young age. 
Heart murmur (non-haemic), gallop sounds, arrhythmia, jugular vein 
distention and pulse may be present. 
Differences – Low protein / low cellularity effusion. Hypothermia 
and/or hypotension are common. Pyrexia, hyperglobulinaemia and 
jaundice are not features 
Diagnosis – Echocardiography 
✓ = feature shared with FIP (NB: absence does not rule it out as a differential); * NB: risk of false-negative if collected after antibiotics 179 
administered; LNs = lymph nodes 180 
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Table 3 Commonly encountered changes on routine clinicopathological analysis seen in cats 181 
with feline infectious peritonitis. 182 
Haematology Anaemia (often mild & non-regenerative) 
Microcytosis 
Lymphopenia 
Neutrophilia (+/- left shift) 
Serum biochemistry Hyperglobulinaemia* (often polyclonal gammopathy) 
Hypoalbuminaemia (secondary to acute phase protein 
response; compensatory for hyperglobulinaemia 
Hyperbilirubinaemia 
Low albumin to globulin ratio 
Increased liver enzyme activities (primarily hepatocellular, 
esp. AST) 
 183 
Further support for FIP may be gained from the measurement of inflammatory markers. 184 
Serum protein electrophoresis is a crude way of determining the presence and nature of an 185 
inflammatory response, particularly where there is a hyperglobulinaemia. The most 186 
frequently encountered change in cats with FIP is a polyclonal gammopathy, indicating a 187 
non-clonal increase in antibodies; however, a small number of cats present with a 188 
monoclonal gammopathy (Taylor et al., 2010), whilst others show increases in the alpha2-189 
globulin fraction (reflecting an increase in acute-phase proteins (APPs))(Stranieri et al., 190 
2017). APPs are made in the liver in response to cytokines released from activated 191 
macrophages and monocytes. Marked increases (>1.5 mg/mL) in serum 1-acid 192 
glycoprotein (AGP) can support a diagnosis of FIP (Paltrinieri et al., 2007, Duthie et al., 1997, 193 
Hazuchova et al., 2017). Other APPs, serum amyloid A and haptoglobin, have been assessed 194 
in the diagnosis of FIP but were both less sensitive and specific than AGP (Duthie et al., 195 
1997, Hazuchova et al., 2017). Overall, increased AGP (or other APPs) in serum, despite 196 
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supporting a diagnosis of FIP, is not confirmatory and may be limited by cost, availability and 197 
turnaround time.  198 
 199 
Clinicians vary as to whether they perform FCoV serology or not in suspected cases. 200 
Although a positive result indicates exposure to FCoV, many clinically healthy cats have 201 
positive, often high, antibody titres, whilst a small proportion of cats with both effusive and 202 
non-effusive FIP are seronegative. Diagnosis of FIP should never be made based upon 203 
positive serology alone. Faecal RT-qPCR has replaced serology in monitoring the effect of 204 
control measures in the management of FCoV infection within a breeding cattery.  205 
 206 
Imaging (see Figure 4 and Figure 5) can be useful, in that it can often identify areas of 207 
pathology (e.g. mass lesion; effusion) that may prove useful to sample as well as guiding 208 
sample acquisition (e.g. ultrasound-guided needle biopsy). However, imaging alone cannot 209 
be used to make a diagnosis of FIP.  210 
To provide a definitive diagnosis of FIP, cytological or histopathological changes consistent 211 
with FIP (i.e. pyogranulomatous inflammation) should be identified and subsequently co-212 
localised with FCoV antigen, using immunostaining for viral antigen. More recently RT-PCRs 213 
have also been used to support a diagnosis of FIP (see Box 2). 214 
 215 
In effusive FIP, sampling the effusion is the single most useful diagnostic step in confirming a 216 
diagnosis. For this reason, where effusions are not evident on initial evaluation, repeated 217 
ultrasonography to identify any small volume effusion is recommended (Figure 4) and may 218 
facilitate sampling of small pockets of fluid. FIP effusions (Figure 8) are usually clear, poorly 219 
cellular (total nucleated cell count <5x109/L), yellow, viscous, protein-rich (with a total 220 
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protein concentration of >35g/L), have a low albumin to globulin ratio, and have a positive 221 
Rivalta test (Box 1). However, in some cats the effusions might be cloudy, of slightly lower 222 
protein levels (e.g. in cats that were not originally markedly hyperproteinaemic, or following 223 
repeated abdominocentesis), or contain much higher cell counts (up to 20x109/L). 224 
Cytological examination usually reveals pyogranulomatous inflammation with macrophages, 225 
non-degenerate neutrophils and few lymphocytes. Effusion AGP concentrations may also be 226 
useful in supporting a diagnosis of FIP, potentially affording greater sensitivity and 227 
specificity than serum measurements (Duthie et al., 1997, Hazuchova et al., 2017), but are 228 
not confirmatory. Positive FCoV antigen immunostaining is strongly supportive of a 229 
diagnosis of FIP. However, false-negatives occur in 5-43% of cats with FIP (Hartmann et al., 230 
2003, Paltrinieri et al., 1999), particularly in low cellularity samples, and false-positives have 231 
been reported in up to 30% of cases (Hartmann et al., 2003, Felten et al., 2017b, Litster et 232 
al., 2013), including cats with neoplasia or cardiac disease. False-positive results may be 233 
dependent on technique, methodology or laboratory used, therefore checking the 234 
specificity and use of internal controls with the laboratory used is recommended when 235 
interpreting results. 236 
 237 
Box 1: The Rivalta test  238 
This test is a simple inexpensive, point-of-care test to differentiate a transudate from an 239 
inflammatory effusion. It does not replace more advanced analysis in-house or at external 240 
laboratories, but it can facilitate decision-making particularly in financially constrained 241 
settings, particularly where tests to quantify effusion protein concentrations are not 242 
available.  243 
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Rivalta test is more useful at ruling out FIP, than ruling it in: over 90% of FIP effusions are 244 
Rivalta test positive (Hartmann et al., 2003, Fischer et al., 2012); positive results are also 245 
seen with bacterial peritonitis and neoplastic exudates; and low protein, non-inflammatory 246 
exudates (such as those see with cardiac failure or hypoproteinaemia) are typically negative.  247 
Method: 10 ml distilled water mixed with 2-3 drops of white vinegar in a test tube or 248 
universal container; one drop of effusion is added carefully to the top 249 
* Negative = dispersion of the drop of effusion 250 
* Positive = the drop of effusion retains its shape and floats slowly to the bottom of the tube 251 
or sits on the surface of the water 252 
 253 
For cats with suspected non-effusive FIP and accessible mass lesions (e.g. mesenteric 254 
lymphadenomegaly) fine needle cytology may be considered. Whilst in cats where CNS (see 255 
Figure 5) or ocular signs (see Figure 6) predominate, more specialist techniques to obtain 256 
samples of cerebrospinal fluid or aqueous humour for analysis are discussed in the literature 257 
but rarely performed in first-opinion practice. Cytology typically reveals non-septic 258 
pyogranulomatous to granulomatous inflammation; however, this is only documented in 42 259 
to 82% of cats with FIP, and up to 30% samples from cats without FIP (Gruendl et al., 2017, 260 
Felten et al., 2018, Giordano et al., 2005). Positive immunostaining for FCoV antigen can 261 
provide further support for FIP. However, as with cytological analysis alone, false-negatives 262 
occur >15% of CSF samples (Gruendl et al., 2017), >35% of aqueous humour samples (Felten 263 
et al., 2018), and 11-53% of tissue aspirates (Felten et al., 2019, Giordano et al., 2005) from 264 
cats with FIP, with false-positives reported in ~20% of samples from cats without FIP, 265 




Although, until recently the reference standard for the diagnosis FIP, histopathology alone 268 
can be non-diagnostic, equivocal or misleading in some cases (Pedersen, 2009, Giuliano et 269 
al., 2018, Giordano et al., 2005), particularly where needle-core samples are collected blind. 270 
Many now consider the demonstration of FCoV antigen within granuloma-associated 271 
macrophages by immunostaining as the reference standard, but it is subject to the similar 272 
limitations to histology albeit with 100% specificity. In a recent large study, only 62% of 273 
tissue samples from cats with FIP revealed FCoV-positive lesions (Barker et al., 2017). 274 
However, it should be noted that all the samples in this study were collected post-mortem, 275 
visibly normal tissues were frequently sampled in addition to grossly abnormal tissues, and 276 
at least one tissue sample per cat was diagnostic for FIP. Wherever possible grossly 277 
abnormal tissue should be sampled to maximise the likelihood of achieving a diagnosis. 278 
 279 
Box 2: The use and abuse of reverse-transcriptase PCR (RT-PCR) in the diagnosis of FIP 280 
FCoV RT-PCR, when designed appropriately, is a very sensitive and specific assay for the 281 
detection of FCoV within samples, and is generally more sensitive than immunostaining for 282 
FCoV antigen in tissues (Barker et al., 2017). However, it cannot co-localise virus to 283 
cytological / histological lesions, merely to the samples in which those changes are present. 284 
Following intestinal infection with FCoV, most cats develop a viraemia, disseminating virus 285 
throughout the body. Cat without FIP can therefore have detectable virus within blood, 286 
effusions and tissues – albeit at a lower frequency and viral copy number. Due to low 287 
circulating levels of viraemia, use of RT-PCR of whole blood in cats with suspected FIP is not 288 




In a recent large study, all but one cat of 57 (98%) with FIP had at least one tissue positive 291 
for FCoV by quantitative RT-PCR, as compared to 12 of 45 cats without FIP (Barker et al., 292 
2017); viral copy numbers were also significantly higher in the positive samples from cats 293 
with FIP than those without FIP. Further investigation of the single cat with FIP and a 294 
negative RT-PCR result revealed the FCoV present to have multiple mutations in the 295 
sequence normally detected by the RT-PCR assay, resulting in its failure. Whilst, none of the 296 
cats without FIP (including those with a positive RT-PCR result) had histopathological 297 
evidence of granulomatous disease or positive immunostaining. 298 
 299 
RT-PCR has been applied to cytological samples. Most (72-100%) effusions from cats with 300 
FIP are RT-PCR positive, cf. only two false-positives out of 76 samples from cats without FIP 301 
across three studies (Barker et al., 2017, Felten et al., 2017c, Stranieri et al., 2018). Most (18 302 
of 20; 90%) mesenteric lymph node aspirates from cats with non-effusive FIP are RT-PCR 303 
positive (Dunbar et al., 2018); however, one false-positive result (out of 20 cats) did occur in 304 
a cat seropositive for FCoV. Detection of FCoV in CSF by RT-PCR from cats with FIP is 305 
variable, ranging from 21% to 86% (Barker et al., 2017, Doenges et al., 2016, Foley et al., 306 
1998, Emmler et al., 2019), whereas, RT-PCR was negative in all control cats. Detection of 307 
FCoV in aqueous humour from cats with FIP was poor (25%), and no control cats were 308 
tested (Emmler et al., 2019). 309 
 310 
Additional analysis has been applied to RT-PCR-positive samples to determine whether the 311 
FCoV present carries genetic mutations that have been said to be associated with FIP. The 312 
use of Spike gene mutation analysis has been most frequently studied for this purpose, 313 
albeit using different techniques, different sample types and with different conclusions. 314 
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Where a highly sensitive method (pyrosequencing) was employed to evaluate the Spike 315 
gene, mutations were detected in FCoV-positive tissue from 15 of 17 (88%) samples from 316 
cats without FIP as compared to 202 of 206 (99%) samples from cats with FIP (Barker et al., 317 
2017). Other techniques (e.g. allelic discrimination) that require a relatively high viral copy 318 
number in the sample to generate a result (often not present in cats without FIP) and 319 
consider a result where sequencing has failed to be negative, will increase the test 320 
specificity by a modest amount by reducing, but not eliminating, the number of false-321 
positives; however, the detection of true-positives results in cats with FIP (i.e. the test 322 
sensitivity) is more markedly reduced (Emmler et al., 2019, Felten et al., 2017a). 323 
 324 
In conclusion, although a positive RT-PCR result on fluid, effusions, aspirates and tissue can 325 
provide strong support for a diagnosis of FIP (particularly for CSF), both false positives and 326 
false negatives occur such that RT-PCR should not be solely relied upon to make a diagnosis. 327 
Further, Spike gene analysis is either of little benefit over RT-PCR at removing false-positives 328 
(i.e. when pyrosequencing is used), or markedly increases the number of false-negatives (i.e. 329 
when allelic discrimination is used) and may inadvertently cast doubt on a diagnosis of FIP in 330 
a with FIP potentially delaying treatment. 331 
 332 
NB: RT-PCR of faeces is not a test for FIP, it is a test for FCoV shedding (which can be 333 
intermittent). Most cats that have a positive faecal FCoV result will not go on to develop FIP, 334 
and only two in every three cats with FIP are shedding FCoV at time of euthanasia (Barker et 335 
al., 2017). It is only of use in special circumstances (e.g. attempting to identify shedders 336 




Often, and especially in non-effusive FIP, collection of biopsies from tissues with gross 339 
lesions is necessary to achieve a definitive diagnosis. In the absence of a definitive diagnosis, 340 
or pending confirmatory tests, available results form the basis of discussion as to whether 341 
further, invasive, investigation is likely to change treatment options and whether to start 342 
treatment. This can been frustrated by the geographical restriction (outside the UK) of some 343 
tests (e.g. AGP, immunocytochemistry, immunohistochemistry, and RT-PCR) that would 344 
otherwise be strongly supportive of a diagnosis of FIP. If euthanasia is performed without a 345 
definitive diagnosis, post-mortem examination is strongly recommended to assess whether 346 
gross findings (with histopathology if funds allow) are consistent with a diagnosis of FIP. 347 
 348 
Treatment & Prognosis 349 
Potential alternative diagnoses, such as toxoplasmosis and mycobacterial infection, should 350 
be ruled out and a definitive diagnosis of FIP made prior to considering treatment; however, 351 
the reality is that treatment is often started when as close to a definitive diagnosis of FIP as 352 
possible has been achieved, taking into account the overall clinical picture alongside owner 353 
preferences and finances. A lack of definitive diagnosis makes it impossible to know 354 
whether a treatment response indicates efficacy against FIP, or a missed alternative 355 
diagnosis. Treatments administered may also interfere with the sensitivity and specificity of 356 
future diagnostic test results. A paucity of placebo- or ‘current best-treatment’-controlled 357 
clinical trials of cats with definitively confirmed FIP limits treatment recommendations. 358 
Currently, no licensed drug is available that has proved effective in curing FIP.  359 
 360 
Prognosis for cats with effusive disease is grave, with death or euthanasia within days to 361 
occasionally weeks in most cases. The prognosis for cats with non-effusive disease is also 362 
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poor, with death or euthanasia within weeks to months in most cases. However, it is not 363 
necessary to euthanase immediately if the cat still has a reasonable quality of life. It is 364 
possible to maintain palliative treatment for as long as weight and activity are maintained. 365 
Rarely some individuals have survived for months to sometimes years, often with supportive 366 
treatment, but it is unclear as to whether the treatment administered influenced survival.  367 
 368 
Treatment is currently limited to supportive care. Cats, once anorexic, can quickly become 369 
dehydrated; therefore, simple fluid therapy, correction of electrolyte disturbances, and 370 
encouraging them to eat can be extremely useful at improving their quality of life. The value 371 
of removing fluid effusions in cats with FIP has been debated. Thoracocentesis is indicated 372 
where effusion has resulted in dyspnoea. Abdominocentesis is controversial and may be 373 
detrimental due to exacerbation of dehydration, although some authors have described 374 
fluid drainage followed by intracavitary corticosteroid administration. 375 
 376 
Given that FIP has a significant immune-mediated component, treatment to either suppress 377 
or modify the immune response can be considered. Corticosteroids are the most frequently 378 
used medication – and some cats receive benefit from them, particularly in terms of quality 379 
of life. However, there are no controlled studies to prove beneficial effect, only anecdotal 380 
reports, and they appear to do very little for the viral infection itself. Doses are empirical 381 
(prednisolone 2-4mg/kg/day orally) and can be tapered slowly to response.  382 
 383 
Many different drugs have been considered for the treatment of FIP. Cyclophosphamide, 384 
ciclosporin A and anti-TNF- antibodies have been anecdotally used to prolong survival, but 385 
no controlled studies have been performed. Pentoxifylline has also been anecdotally used to 386 
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manage the vasculitis; however, in a placebo-controlled trial of the related drug, 387 
propentofylline, no benefit was found (Fischer et al., 2011). Interferons are also commonly 388 
used, on the basis of positive anecdotal reports; however, a placebo-controlled clinical trial 389 
failed to demonstrate a clinically relevant benefit (Ritz et al., 2007). Polyprenyl 390 
immunostimulant has limited data to support its use with significant limitations (including 391 
lack of control treatment group and limited diagnostic criteria for FIP) (Legendre et al., 392 
2017); however, it is possible that it may improve survival times in the milder forms of non-393 
effusive FIP without detrimental impact on the patient. Herbal medication has also been 394 
suggested for cats with FIP, often with no scientific data to support its use. 395 
 396 
Recently described promising new, but as yet unlicensed, drugs comprise viral protease 397 
inhibitors and nucleoside analogs. FCoVs produce large viral proteins (e.g. the gene 398 
encoding polyprotein 1 forms a large component of the FCoV genome, see Figure 1) that are 399 
cleaved into smaller functioning units by proteases. Inhibitors of these proteases therefore 400 
affect viral production. The protease inhibitor GC376 has produced remarkable responses in 401 
both experimentally-induced and naturally-occurring FIP, with six of eight cats with 402 
experimental-induced FIP alive at 8 months and 19/20 cats with naturally-occurring FIP 403 
showing a positive response, which was sustained in seven cats (Kim et al., 2015, Pedersen 404 
et al., 2018). The nucleoside analog GS-441524 acts as an alternative substrate and RNA-405 
chain terminator of the viral RNA polymerase, thus interfering with FCoV replication. It too 406 
has produced remarkable responses in both experimentally-induced and naturally-occurring 407 
FIP, with all 10 cats with experimental-induced FIP alive at 8 months and 26/31 cats with 408 
naturally-occurring FIP having a positive response, which was sustained in 25 cats (Murphy 409 
et al., 2018, Pedersen et al., 2019). Unfortunately, both the protease inhibitor GC376 and 410 
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the nucleoside analog GS-441524 appear to poorly penetrate the blood-brain and blood-eye 411 
barriers, likely accounting for increased likelihood of relapses involving the nervous system 412 
or lack of initial response to treatment in study cats presenting with neurological or ocular 413 
signs of FIP. The use of higher than previously reported doses of these agents, along with 414 
extended courses, have been suggested for cases of neurological or ocular FIP; however, 415 
more studies are warranted. 416 
 417 
The authors are aware that, in the absence of commercially available licensed products, 418 
some UK cat owners have obtained black-market forms of both GS-441524 and GC376 via 419 
the internet for the treatment of FIP in their pet. By their nature, these black-market 420 
products are of unknown quality, efficacy, toxicity and longevity, and therefore cannot be 421 
prescribed by veterinary surgeons for their patients. 422 
 423 
A ‘nutritional supplement’ (Mutian) containing a novel adenosine nucleoside analogue 424 
(Mutian® X; reported to be different to GS-441524) has been marketed worldwide, primarily 425 
at cat owners, for the treatment of FIP (Addie et al., 2020). However, there is only limited 426 
published research describing its use to stop faecal shedding of virus (Addie et al., 2020). 427 
There is currently no peer-reviewed evidence base upon which to recommend its use in cats 428 
with FIP. Further, according to both the Veterinary Medicines Directorate (UK) and the Food 429 
and Drug Administration (USA), nutritional supplements may not be presented with 430 
medicinal claims (e.g. the ability to cure cats of FIP), otherwise they would be considered as 431 
a veterinary medication requiring authorisation.  432 
 433 
Prevention and in-contact cats 434 
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One of the most frequent questions from owners following the diagnosis of FIP in one of 435 
their cats is what do with the other cats in the household. For the major considerations see 436 
Box 3. As spread of FCoV is most of a concern amongst large groups, reduction in 437 
environmental viral load through improved hygiene is key. Appropriate care in cleaning and 438 
use of disinfectants (see (Addie et al., 2015) for more information) to reduce environmental, 439 
including fomite, contamination is necessary. This includes maintenance of toileting facilities 440 
including: sufficient litter-trays per cat; siting litter-trays away from food and water; and use 441 
of cat litter that may have enhanced neutralisation of FCoV to limit fomite spread (e.g. dust-442 
free clumping Fuller’s earth litter)(Addie et al., 2019). Although achievement of a FCoV-free 443 
household or kittens (e.g. via early weaning) is technically possible, it is not without 444 
significant cost and potentially welfare concerns – more information can be found in the 445 
latest ABCD guidelines on Feline Infectious Peritonitis (www.abcdcatsvets.org/feline-446 
infectious-peritonitis/). 447 
 448 
Minimising host risk factors, particularly relating to stress of conflict or overcrowding, is also 449 
recommended. Further, in breeding situations where particular sire and queen 450 
combinations have resulted in cases of FIP across multiple litters, retiring of one or both cats 451 
from the breeding programme should be considered in case they are conferring increased 452 
genetic risk of FIP. 453 
 454 
The FIP vaccine (Felocell® FIP, Zoetis), where available, is not recommended for use in cats 455 
under 16 weeks age or considered to be of benefit to cats that are already FCoV antibody-456 
positive cats. It is therefore of limited usefulness as initial exposure to FCoV is considered to 457 
be much earlier than 16 weeks in most cases. Further, as current serological tests are unable 458 
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to differentiate vaccinated from naturally-exposed cats, it is of no benefit if trying to 459 
maintain a FCoV-free household. The FIP vaccine is either ‘not recommended’ or considered 460 
‘non-core’, under current AAFP, ABCD, and WSAVA vaccination guidelines (and not even 461 
discussed in the BSAVA vaccination guidelines).  462 
 463 
Box 3: When one cat gets FIP, what to do with the other cat(s) in the household? 464 
* Where more than one cat is being considered (i.e. the one with FIP, an its in-contact), an 465 
accurate diagnosis becomes more important in order to guide advice 466 
* In-contact cats will be at slightly increased risk cf. the general population, particularly if 467 
they are direct siblings (estimated 2x risk), due to shared viral, environmental and possibly 468 
genetic factors – but none of these can be changed at time of diagnosis! 469 
* Whilst cats can pass FCoV that causes intestinal infection between each other, they are 470 
not thought to be able to horizontally pass the mutated FCoV that directly causes FIP 471 
between themselves (i.e. the mutation is a spontaneous event that happens within 472 
individuals). Given that the cat with FIP would have had historical intestinal infection with 473 
FCoV, it is likely that the other cat(s) in the household would have been infected historically 474 
too 475 
* Removal or isolation of a cat with (suspected / proven) FIP from a household is not 476 
indicated, and would likely negatively impact on the sick cat 477 
* As the household environment (inc. fomites) is likely contaminated with FCoV (particularly 478 
if there are 5+ cats in the household, to maintain continuous infection) – improved hygiene 479 
(particularly litter tray-associated) is strongly recommended 480 
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* As stress is associated with the development of FIP – reducing household stress (e.g. due 481 
to conflict, overcrowding, or continued breeding) is recommended, as is deferral of non-482 
essential, elective procedures (e.g. microchipping; neutering) 483 
* As FCoV can survive under appropriate conditions for up to 7 weeks in the environment 484 
and the loss of a house-mate will be stressful for the remaining cats (and therefore may 485 
temporarily induce FCoV shedding in carriers) – immediate ‘replacement’ of the deceased 486 
cat is strongly discouraged (for at least 3 months). These replacements may be naïve to the 487 
FCoV isolate circulating in the household, are typically young (i.e. in the highest risk category 488 
for going on to develop FIP following exposure to the virus), may share some genetic risk 489 
factors (i.e. if from the same source as the deceased cat), and may well cause stress and 490 
conflict within the household (i.e. owners often have the misconception that the remaining 491 
cat(s) need the company of another cat). 492 
* Faecal shedding by remaining cats (e.g. by weekly faecal PCRs on 3-4 occasions) could be 493 
considered prior to the introduction of a new cats, but this would not completely eliminate 494 
risk (as shedding is intermittent), and a significant number of cats are infected with FCoV 495 




FIP is a common differential for disease in, often younger, cats. Obtaining a definitive 500 
diagnosis by minimally-invasive means can be difficult, and a balance of probability might 501 
need to be used to guide further testing. Although currently treatment is limited, novel anti-502 




ADDITIONAL READING: 505 
Tasker, S. (2018) Diagnosis of feline infectious peritonitis: Update on evidence supporting 506 
available tests. Journal of Feline Medicine and Surgery 20 228-243 507 
The most up to date version of the ABCD guidelines on Feline Infectious Peritonitis (Addie et 508 
al. 2019) are available online www.abcdcatsvets.org/feline-infectious-peritonitis/ 509 
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Figure 1 Schematic diagram of the feline coronavirus genome (approximately 29,250 683 
nucleotides in length excluding the polyA tail) with component genes and nucleotide scale. 684 
Note that over two thirds of the genome comprises the gene that encodes non-structural 685 
polyprotein 1. 686 
 687 
Figure 2 Schematic drawing of a feline coronavirus virion with relative position of structural 688 
proteins and genomic single-stranded RNA (ssRNA) indicated. The spike glycoprotein trimers 689 
project from the surface of the virus, resulting in the ‘crown’-like appearance when viewed 690 
under transmission electron microscopy from which they are named. 691 
  692 
Figure 3 Numerous granulomas (black arrows) within a sectioned kidney from a two-year-693 
old male neutered cat with feline infectious peritonitis. The cat was presented with an acute 694 
history of lethargy and inappetence. Physical examination revealed a thin body condition, 695 
pale and icteric mucous membranes, subtle unilateral anterior uveitis and bilateral 696 
renomegaly. Blood analysis documented severe anaemia (haematocrit 7.8%; reference 697 
interval [RI] 27-47%), hyperglobulinaemia (83g/L; RI 21-51g/L) and jaundice (31µmol/L; RI 698 
<10µmol/L). On post-mortem examination a moderate volume of ascites was present, 699 
alongside small volume pleural and pericardial effusions. Both kidneys were enlarged with 700 
margins distorted by vascularised mass lesions. Pyogranulomatous lesions were found on 701 
histopathology of samples collected throughout the body (including the iris), with presence 702 




Figure 4 Ultrasonographic images of two cats with feline infectious peritonitis. The first cat 705 
(A) had a large mid-abdominal mass on examination, which was identified as being 706 
mesenteric lymph node using ultrasound (yellow calliper). The second cat (B) also had 707 
enlarged abdominal lymph nodes (yellow calliper); however, a small volume of ascites was 708 
also visible (white arrow). Ultrasound enabled guided sampling of both the enlarged lymph 709 
nodes and the ascites.  710 
 711 
Figure 5 Photo (A) of a 6-month-old male entire Ragdoll, presented with a 48-hour history of 712 
altered behaviour and a 24-hour history of hind-limb paresis, reduced appetite, nystagmus 713 
and mild head tilt. Neurolocalisation was most consistent with central vestibular syndrome, 714 
mostly likely a result of cerebellar disease. Routine haematology and serum biochemistry 715 
were unremarkable. MRI (B; T2-weighted midline sagittal view) revealed severe 716 
hydrocephalus with dilation of the entire ventricular system of the brain and secondary 717 
herniation of the cerebellum, the latter likely accounting for the majority of clinical signs. 718 
Ultimately, the presence of feline coronavirus was confirmed with reverse-transcriptase 719 
polymerase chain reaction of cerebrospinal fluid, alongside histopathology and 720 
immunostaining of meningeal tissue samples confirming a diagnosis of feline infectious 721 
peritonitis. 722 
 723 
Figure 6. Feline infectious peritonitis is a major differential for uveitis, manifestations of 724 
which include: changes in iris colour, thickness and texture; dyscoria (abnormal shape of the 725 
pupil); anisocoria (unequal pupil sizes); sudden loss of vision; hyphaema; keratic precipitates 726 
(‘mutton fat’ deposits on the ventral corneal endothelium); chorioretinitis; retinal 727 
detachment; and aqueous / vitreous flare. These changes may be subtle and unilateral (A; 728 
 
 37 
mild iridial changes, aqueous flare and keratic precipitates [white arrow] of the right eye in a 729 
8-month-old Chinchilla Persian with pyrexia of unknown origin; images courtesy of Caroline 730 
Smith), or bilateral and severe (B; bilateral severe fibrinous, flocculent, aqueous flare 731 
limiting examination of the interior of the eye; images courtesy of Vim Kumaratunga), 732 
where assessment of the retina is possible changes may be present there too (C; severe 733 
bilateral chorioretinitis including haemorrhage and granulomata [pink and red arrow]; 734 
aqueous flare and retinal oedema results in the image appearing to be out of focus; images 735 
courtesy of Vim Kumaratunga) 736 
 737 
Figure 7 Diagnostic approach to cats with suspected FIP 738 
 739 
Figure 8 Although effusions from cats with feline infectious peritonitis are typically clear, 740 
viscous with a tendency to froth when agitated, and with a slightly yellow tinge, reflecting a 741 
low cellularity (<5 x109/L total nucleated cell count), high concentration of predominantly 742 
inflammatory proteins (>35g/L), and patient jaundice respectively, their gross appearance 743 
can be variable.  744 
